Abstract: Objective To investigate the efficacy of Omalizumab in the treatment of children with moderate to severe allergic asthma and chronic sinusitis. Methods The clinical data of children with moderate and severe allergic asthma and chronic sinusitis treated with Omalizumab from September 2020 to April 2022 were retrospectively analyzed. A comparison was performed on the changes of childhood asthma control test(C-ACT), fractional concentration of exhaled nitric oxide(FeNO), forced expiratory volume in the first second percentage to predicted value(FEV₁% pred)and small airway function, the improvement of chronic sinusitis symptoms,before and after treatment with Omalizumab. Results A total of 26 children completed treatment and follow-up. After 16 weeks of Omalizumab treatment, asthma symptoms and lung function were improved. Compared to pre-treatment, the C-ACT score increased from(15.57±3.25)score to(24.98±5.21)score(F=15.711 2, P<0.001)and FeNO decreased from(31.55±15.57)ppb to(19.86±9.80)ppb(F=4.426 5, P=0.002 2). Lung function indicators showed that FEV₁%pred and FEV₁/forced vital capacity(FEV₁/FVC)increased post-treatment, but the differences were not statistically significant(P=0.995 4, P=0.938 2). The maximal expiratory flow percentage of the predicted value, forced expiratory flow at 75% to predicted value, forced expiratory flow at 50% to predicted value all increased significantly(P=0.047 7, P=0.000 5, P<0.001). The symptoms of sinusitis were also significantly improved, and the visual analogue scale score increased from 6.40±2.98 pre-treatment to 0.85±0.40 post-treatment(t=27.241 9, P<0.001). Conclusion Omalizumab can significantly improve the clinical symptoms, lung function indicators and quality of life of children with moderate and severe allergic asthma and chronic sinusitis.

Key words: Omalizumab, Allergic asthma, Chronic sinusitis, Lung function